*Communicable Diseases Intelligence*, Year , Volume

Publication date:

<http://health.gov.au/cdi>

Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP)

Bloodstream Infection Annual Report 2022

Geoffrey W Coombs, Denise A Daley, Princy Shoby, Shakeel Mowlaboccus, on behalf of the Australian Group on Antimicrobial Resistance

# Abstract

From 1 January to 31 December 2022, fifty-five institutions across Australia participated in the Australian Enterococcal Surveillance Outcome Program (AESOP). The aim of AESOP 2022 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to characterise the molecular epidemiology of the Enterococcus faecium isolates. Of the 1,535 unique episodes of enterococcal bacteraemia investigated, 92.8% were caused by either E. faecalis (52.9%) or E. faecium (39.9%). Ampicillin and vancomycin resistance were not detected in E. faecalis but were detected in 95.4% and 46.9% of E. faecium respectively. One E. faecalis isolate, with a daptomycin minimum inhibitory concentration (MIC) of 8.0 mg/L, harboured the F478L GdpD mutation. One E. faecium with a daptomycin MIC of 24.0 mg/L harboured the A20D Cls mutation; both mutations are known to be associated with daptomycin resistance. Two E. faecium isolates, one with a linezolid MIC ≥ 256 mg/L and the other with a linezolid MIC of 16 mg/L, harboured the 23S rRNA G2576T mutation, a mutation associated with linezolid resistance in enterococci.

Overall, 48.8% of E. faecium harboured either the vanA or the vanB gene, of which 28.0% harboured vanA and 72.0% harboured vanB. The percentage of vancomycin-resistant E. faecium bacteraemia isolates in Australia remains substantially higher than that recorded in most European countries. The E. faecium isolates consisted of 62 multi-locus sequence types (STs); 85.5% of isolates were classified into eight major STs each containing ten or more isolates. All major STs belonged to clonal complex (CC) 17, a major hospital-adapted polyclonal E. faecium cluster. The major STs (ST17, ST78, ST80, ST117, ST555, ST796, ST1421, and ST1424) were each found across most regions of Australia. The predominant ST was ST17, which was identified in all regions. Overall, 53.7% of isolates belonging to the eight major STs harboured the vanA or vanB gene. AESOP 2022 has shown that enterococcal bacteraemia episodes in Australia are frequently caused by polyclonal ampicillin-resistant high-level gentamicin resistant vanA- or vanB-positive E. faecium which have limited treatment options.

Keywords: Australian Group on Antimicrobial Resistance (AGAR); antimicrobial resistance surveillance; Enterococcus faecium; Enterococcus faecalis; vancomycin resistant enterococci (VRE); bacteraemia

# Background

Globally Enterococcus is believed to account for approximately 10% of all bacteraemia cases and is the fourth and fifth leading cause of sepsis in North America and Europe, respectively. In the 1970s, healthcare-associated enterococcal infections were primarily due to Enterococcus faecalis, but there has been a steady increasing prevalence of E. faecium nosocomial infections.1–3 Worldwide, the increase in nosocomial E. faecium infections has primarily been due to the expansion of polyclonal hospital-adapted clonal complex (CC) 17 strains. While innately resistant to many classes of antibiotics, E. faecium has further demonstrated a remarkable capacity to evolve new antimicrobial resistances. In 2009, the Infectious Diseases Society of America highlighted E. faecium as one of the key problem bacteria or ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) requiring new therapies.4

The Australian Group on Antimicrobial Resistance (AGAR) is a network of laboratories located across Australia that commenced surveillance of antimicrobial resistance in Enterococcus species in 1995.5 In 2011, AGAR commenced the Australian Enterococcal Sepsis Outcome Program,6,7 now known as the Australian Enterococcal Surveillance Outcome Program (AESOP). The objective of AESOP 2022 was to determine the proportion of E. faecalis and E. faecium bacteraemia isolates demonstrating antimicrobial resistance, with particular emphasis on:

* assessing susceptibility to ampicillin;
* assessing susceptibility to glycopeptides; and
* the molecular epidemiology of E. faecium.

# Methodology

## Participants

Thirty-three laboratories servicing 55 institutions from all Australian states and mainland territories.

## Collection period

From 1 January to 31 December 2022, the 33 laboratories collected all enterococcal species isolated from blood cultures. Enterococci of the same species and antimicrobial susceptibility profiles isolated from a patient’s blood culture within 14 days of the first positive culture were excluded. A new enterococcal bacteraemia episode in the same patient was recorded if it was confirmed by a further culture of blood taken more than 14 days after the initial positive culture. Data were collected on age, sex, dates of admission and discharge (if admitted), and mortality at seven and 30 days from date of blood culture collection. To avoid interpretive bias, no attempt was made to assign attributable mortality. Each episode of bacteraemia was designated as ‘hospital-onset’ if the first positive blood culture(s) in an episode was collected > 48 hours after admission.

## Laboratory testing

Enterococcal isolates were identified to the species level by the participating laboratories using matrix-assisted laser desorption ionization (MALDI)—MALDI Biotyper (Bruker Daltonics, USA) or Vitek-MS (bioMérieux, France)—or by the Vitek2® (bioMérieux). Antimicrobial susceptibility testing was performed using the Vitek2® (bioMérieux) or the BD Phoenix™ (Becton Dickinson, USA) automated microbiology systems, according to the manufacturer’s instructions. Minimum inhibitory concentration (MIC) data and isolates were referred to the Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, at Murdoch University. Clinical and Laboratory Standards Institute (CLSI)8 and European Committee on Antimicrobial Susceptibility Testing (EUCAST)9 MIC breakpoints were utilised for interpretation.Linezolid and daptomycin non-susceptible isolates and vancomycin-susceptible isolates which harboured the vanA or vanB genes were retested by Etest® (bioMérieux) using the Mueller-Hinton agar recommended by the manufacturer. The control strain used was E. faecalis ATCC® 29212. For all E. faecium received, whole genome sequencing (WGS) was performed by the AMRID Research Laboratory at Murdoch University on the Illumina NextSeq™ 500 platform. The multilocus sequence type (ST) was determined using the PubMLST website; van genes were identified using nucleotide sequences from the NCBI database and a BLAST interface.

Confidence intervals for proportions, Fisher’s exact test for categorical variables, and chi-square test for trend were calculated, if appropriate, using MedCalc for Windows, version 12.7 (MedCalc Software, Belgium).

Approval to conduct the prospective data collection was given by the research ethics committee associated with each participating laboratory.

# Results

From 1 January to 31 December 2022, there were 1,535 unique episodes of enterococcal bacteraemia identified. Although thirteen Enterococcus species were identified, E. faecalis and E. faecium predominated: 812 isolates (52.9%) were E. faecalis and 613 isolates (39.9%) were E. faecium. One hundred and ten enterococci were identified either as E. lactis (previously identified as E. faecium, 29 isolates), E. casseliflavus (21 isolates), E. gallinarum (17 isolates), E. avium (16 isolates), E. raffinosus (13 isolates), E. hirae (5 isolates), E. durans (4 isolates), E. gilvus (2 isolates), E. dispar (1 isolate), E. cecorum (1 isolate) or Enterococcus sp. [not speciated] (1 isolate).

A significant difference was observed in patient sex (p < 0.0001), with 1,034 (67.4%) being male (95% confidence interval [95% CI]: 65.0–69.7). The average age of patients was 64 years, ranging from 0 to 101 years, with a median age of 69 years. Overall, isolates were evenly divided by place of onset: 767/1,535 (50.0%) were community-onset and 768/1,535 were hospital-onset (95% CI: 47.5–52.5). However, a significant difference (p < 0.01) was observed between E. faecium and E. faecalis in place of onset, with only 25.6% (95% CI: 22.2–29.3) of E. faecium episodes being community-onset compared to 67.0% (95% CI: 63.7–70.2) for E. faecalis. All-cause mortality at 30 days, where outcome was known, was 21.2% (95% CI: 19.0–23.5).There was a significant difference in mortality between E. faecalis and E. faecium episodes (17.2% vs 26.9% respectively, p < 0.01). There was also a significant difference in mortality between vancomycin-susceptible and vancomycin non-susceptible E. faecium episodes (19.7% vs 34.4% respectively, p < 0.01).

## *Enterococcus faecalis* phenotypic susceptibility

Apart from erythromycin, high-level gentamicin and tetracycline, acquired resistance was rare amongst E. faecalis isolates (Table 1). Twenty-one E. faecalis isolates (2.6%) were initially reported as linezolid non-susceptible (CLSI breakpoint > 2 mg/L). Four isolates were unavailable for linezolid susceptibility test confirmation. By Etest®, 14 of the 17 referred isolates had a linezolid MIC ≤ 2 mg/L and were therefore considered linezolid susceptible. One isolate with a linezolid MIC of 3.0 mg/L and two isolates with linezolid MICs of 4 mg/L, although intermediate by CLSI criteria, were considered susceptible by EUCAST criteria.

Four isolates were initially reported as daptomycin resistant (≥ 8 mg/L) by CLSI criteria. One isolate was unavailable for confirmation. By Etest®, two of the three referred isolates had a daptomycin MIC < 8 mg/L. The remaining isolate, with a MIC of 8.0 mg/L, harboured the F478L GdpD mutation, a mutation known to be associated with daptomycin resistance.

****Table 1: The number and proportion of *E. faecalis* isolates non-susceptible to ampicillin, penicillin and the non-β-lactam antimicrobials, AGAR, 2022****

|  |  | CLSIa | EUCASTb |
| --- | --- | --- | --- |
| Antimicrobial | *E. faecalis*isolates (n) | Intermediate % (n) | Resistant % (n) | Susceptible, increased exposure % (n) | Resistant % (n) |
| Ampicillin | 807 | – c | 0.0 (0) | 0.0 (0) | 0.0 (0) |
| Benzylpenicillin | 664 | – c | 0.9 (6) | – d | – d |
| Daptomycin | 745 | 38.9 (290) | 0.1 (1) | – d | – d |
| Linezolid | 804 | 0.4 (3) | 0.0 (0) | – c | 0.0 (0) |
| Teicoplanin | 807 | 0.0 (0) | 0.0 (0) | – c | 0.0 (0) |
| Vancomycin | 807 | 0.0 (0) | 0.0 (0) | – c | 0.0 (0) |

a CLSI: Clinical and Laboratory Standards Institute

b EUCAST: European Committee on Antimicrobial Susceptibility Testing.

c No guidelines for indicated species.

d No category defined.

## *Enterococcus faecium* phenotypic susceptibility

The majority of E. faecium were non-susceptible to multiple antimicrobials including ampicillin, erythromycin, high-level gentamicin and tetracycline (Table 2). Overall, 285 E. faecium isolates (46.9%) were phenotypically vancomycin non-susceptible (MIC > 4 mg/L). Sixty-three (9.4%) and 80 (13.2%) isolates were teicoplanin non-susceptible by CLSI and EUCAST criteria, respectively. Fifteen isolates (2.5%) were initially reported as linezolid non-susceptible (CLSI breakpoint > 2 mg/L). Two isolates were unavailable for confirmation. By Etest®, nine of the thirteen referred isolates had a linezolid MIC ≤ 2 mg/L and were therefore considered linezolid susceptible. One isolate with a MIC of 3.0 mg/L and one isolate with a MIC of 4 mg/L by Etest®, although intermediate by CLSI criteria, were considered susceptible by EUCAST criteria. The two remaining isolates, one with a linezolid MIC ≥ 256 mg/L and the other with a linezolid MIC of 16 mg/L, harboured the 23S rRNA G2576T mutation which is associated with linezolid resistance in enterococci. Two isolates were initially reported as daptomycin resistant ≥ 8 mg/L. One isolate was unavailable for confirmation. The other isolate, with an MIC of 24 mg/L, was confirmed as daptomycin resistant. This isolate harboured the A20D Cls mutation, a mutation known to be associated with daptomycin resistance.

****Table 2: The number and proportion of *E. faecium* isolates non-susceptible to ampicillin, penicillin and the non-β-lactam antimicrobials, AGAR, 2022****

|  |  | CLSIa | EUCASTb |
| --- | --- | --- | --- |
| Antimicrobial | *E. faecium*isolates (n) | Intermediate % (n) | Resistant % (n) | Susceptible, increased exposure % (n) | Resistant % (n) |
| Ampicillin | 606 | – c | 95.4 (578) | 0.5 (3) | 95.4 (578) |
| Benzylpenicillin | 480 | – c | 94.2 (452) | – d | – d |
| Daptomycin | 58 | 98.3 (57)e | 1.7 (1) | – d | – d |
| Linezolid | 607 | 0.3 (2) | 0.3 (2) | – c | 0.3 (2) |
| Teicoplanin | 605 | 1.5 (9) | 8.9 (54) | – c | 13.2 (80) |
| Vancomycin | 608 | 1.0 (6) | 45.9 (279) | – c | 46.9 (285) |

a CLSI: Clinical and Laboratory Standards Institute

b EUCAST: European Committee on Antimicrobial Susceptibility Testing.

c No guidelines for indicated species.

d No category defined.

e Susceptible dose-dependent (SDD) category for CLSI. (*E. faecium* are usually SDD to daptomycin.)

## Genotypic vancomycin susceptibility

For 384 (47.3%) of the 812 E. faecalis isolates, vanA/vanB polymerase chain reaction (PCR) results were available. No vanA/vanB genes were detected in E. faecalis.

The presence of vanA or vanB genes was determined by PCR and/or WGS on 560 (91.4%) of the 613 E. faecium isolates. Overall, 267 of the 560 isolates (47.7%) harboured a vanA or vanB gene. Of the vancomycin non-susceptible E. faecium isolates (Vitek2® vancomycin MIC > 4 mg/L), 72 harboured vanA and 186 harboured vanB. The vanA or vanB gene was detected in nine vancomycin-susceptible E. faecium isolates. One isolate with a vancomycin MIC of 2.0 mg/L and teicoplanin MIC of 1.0 mg/L harboured vanA. The eight vanB-positive vancomycin-susceptible isolates had vancomycin MICs ranging from ≤ 0.5 mg/L to 4.0 mg/L.

## *E. faecium* molecular epidemiology

Of the 613 episodes, 560 E. faecium isolates (91.4%) were available for typing by WGS. The 560 isolates were classified into 62 STs, including eight STs with ten or more isolates (Table 3). Of the 54 STs with fewer than ten isolates each, 40 STs were each represented by only one isolate. Overall, 479 (85.5%) of the 560 isolates were grouped into the eight major STs. Using eBURST, all major STs were grouped into CC17.

Geographical distribution of the STs varied (Table 3). Amongst the eight major STs, ST17 (119 isolates), ST78 (110 isolates) and ST80 (45 isolates) were identified in all regions; ST1424 (81 isolates) was identified in all regions except Western Australia and the Northern Territory; ST796 (50 isolates) was identified in all regions except the Australian Capital Territory, the Northern Territory, Queensland and Western Australia; ST1421 (44 isolates) was identified only in New South Wales, Victoria, Queensland and the Australian Capital Territory; ST555 (20 isolates) was identified in all regions except Queensland, Tasmania and the Australian Capital Territory; and ST117 (10 isolates) was identified only in New South Wales, South Australia and Western Australia.

The vanA gene was detected in five major STs (72 isolates from ST17, ST1424, ST80, ST1421 and ST117) (Table 4).The vanB gene was detected in seven of the eight major STs (185 isolates from ST17, ST78, ST1424, ST796, ST80, ST555, and ST117). One minor ST (ST18) harboured one vanA-positive isolate and six minor STs (ST612, ST203, ST2217, ST2430, ST341, and ST2439) harboured at least one vanB-positive isolate.

****Table 3: The number and proportion of major *Enterococcus faecium* sequence types, AGAR, 2022, by jurisdiction****

|  | Percentage, % (n)a |
| --- | --- |
| MLSTb | ACT | NSW | NT | Qld | SA | Tas. | Vic. | WA | Australia |
| ST17 | 6.3 (1) | 8.3 (15) | 7.7 (1) | 52.2 (24) | 17.5 (7) | 40.9 (9) | 14.9 (26) | 52.2 (36) | 21.3 (119) |
| ST78 | 37.5 (6) | 21.1 (38) | 23.1 (3) | 2.2 (1) | 20.0 (8) | 18.2 (4) | 25.3 (44) | 8.7 (6) | 19.6 (110) |
| ST1424 | 12.5 (2) | 30.6 (55) | 0.0 (0) | 6.5 (3) | 2.5 (1) | 18.2 (4) | 9.2 (16) | 0.0 (0) | 14.5 (81) |
| ST796 | 0.0 (0) | 0.6 (1) | 0.0 (0) | 0.0 (0) | 7.5 (3) | 9.1 (2) | 25.3 (44) | 0.0 (0) | 8.9 (50) |
| ST80 | 31.3 (5) | 5.6 (10) | 7.7 (1) | 21.7 (10) | 2.5 (1) | 4.5 (1) | 5.7 (10) | 10.1 (7) | 8.0 (45) |
| ST1421 | 6.3 (1) | 18.3 (33) | 0.0 (0) | 6.5 (3) | 0.0 (0) | 0.0 (0) | 4.0 (7) | 0.0 (0) | 7.9 (44) |
| ST555 | 0.0 (0) | 0.6 (1) | 23.1 (3) | 0.0 (0) | 32.5 (13) | 0.0 (0) | 1.1 (2) | 1.4 (1) | 3.6 (20) |
| ST117 | 0.0 (0) | 1.1 (2) | 0.0 (0) | 0.0 (0) | 2.5 (1) | 0.0 (0) | 0.0 (0) | 10.1 (7) | 1.8 (10) |
| Other types (n = 54) | 6.3 (1) | 13.9 (25) | 38.5 (5) | 10.9 (5) | 15.0 (6) | 9.1 (2) | 14.4 (25) | 17.4 (12) | 14.5 (81) |
| **Total** | **16** | **180** | **13** | **46** | **40** | **22** | **174** | **69** | **560** |

a ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

b MLST: multi-locus sequence type.

****Table 4: The number and proportion of major *Enterococcus faecium* sequence types harbouring vanA/vanB genes, AGAR, 2022****

|  | Percentagea (n) |  |
| --- | --- | --- |
| MLSTb | *vanA* | *vanB* | *vanA* and *vanB* | *vanA* or *vanB* not detected | Total, n |
| ST17 | 0.8 (1) | 2.5 (3) | 0.0 (0) | 96.6 (115) | 119 |
| ST78 | 0.0 (0) | 100.0 (110) | 0.0 (0) | 0.0 (0) | 110 |
| ST1424 | 34.6 (28) | 1.2 (1) | 0.0 (0) | 64.2 (52) | 81 |
| ST796 | 0.0 (0) | 100.0 (50) | 0.0 (0) | 0.0 (0) | 50 |
| ST80 | 6.7 (3) | 4.4 (2) | 0.0 (0) | 88.9 (40) | 45 |
| ST1421 | 81.8 (36) | 0.0 (0) | 0.0 (0) | 18.2 (8) | 44 |
| ST555 | 0.0 (0) | 90.0 (18) | 0.0 (0) | 10.0 (2) | 20 |
| ST117 | 40.0 (4) | 10.0 (1) | 0.0 (0) | 50.0 (5) | 10 |
| Other types (n = 54) | 1.2 (1) | 11.1 (9) | 0.0 (0) | 87.7 (71) | 81 |
| **Total** | **13.0 (73)** | **34.6 (194)** | **0.0 (0)** | **52.3 (293)** | **560** |

a Percentage of total with van genes.

b MLST: multi-locus sequence type.

# Discussion

Enterococci are intrinsically resistant to a broad range of antimicrobials including the cephalosporins and sulfonamides. Because of their ability to acquire additional resistance through the transfer of plasmids and transposons and to disseminate easily in the hospital environment, enterococci have become difficult to treat and provide major infection control challenges.

In AESOP 2022, a total of 39.9% of enterococcal bacteraemia were due to E. faecium, of which 46.9% (95% CI: 42.9–51.0) were phenotypically vancomycin non-susceptible by Vitek2® or BD Phoenix™. However, 48.8% of E. faecium isolates tested (289/592) harboured a vanA/vanB gene, of which 28.0% were vanA-positive. Overall, 81 E. faecium isolates (13.7%) harboured the vanA gene. Over the last five years, there has been a significant decreasing trend in vanA-positive E. faecium in Australia (χ2 for linear trend = 36.41, p < 0.01).10–14 This was primarily due to a decrease in the number of ST1424 isolates. The majority of E. faecium isolates were non-susceptible to multiple antimicrobials including ampicillin, erythromycin, high-level gentamicin and tetracycline.

As the AGAR programs are similar to those conducted in Europe, comparison of Australian antimicrobial resistance data with other countries is possible. In the 2021 European Antimicrobial Resistance Surveillance Network (EARS-Net) program, the national percentages of vancomycin-resistant E. faecium ranged from 0.0% in Luxembourg to 66.4% in Lithuania.15,16

The AESOP 2022 survey confirms the incidence of vancomycin resistant E. faecium bacteraemia in Australia continues to be a significant problem.

Eight (4.1%) of the 194 vanB-positive E. faecium and one (1.4%) of the 73 vanA-positive E. faecium isolates had a vancomycin MIC at or below the CLSI and EUCAST susceptible breakpoint (≤ 4 mg/L) and therefore would not have been identified using routine phenotypic antimicrobial susceptibility methods.

By WGS, E. faecium was shown to be polyclonal, consistent with the known plasticity of the enterococcal genome. The eight major E. faecium STs identified form part of CC17, a global hospital-derived lineage that has successfully adapted to hospital environments. CC17 is characteristically ampicillin- and quinolone-resistant and subsequent acquisition of vanA- or vanB- containing transposons by horizontal transfer in CC17 clones has resulted in multi-resistant enterococci with pandemic potential.

In AESOP 2022, eight E. faecium STs predominated: ST17 (of which 0.8% of isolates harboured vanA, 2.5% vanB genes); ST78 (100% vanB); ST1424 (34.6% vanA, 1.2% vanB); ST796 (100% vanB), ST80 (6.7% vanA, 4.4% vanB); ST1421 (81.8% vanA, 0% vanB), ST555 (0% vanA, 90% vanB), and ST117 (40.0% vanA, 10.0% vanB).

# Conclusions

The AESOP 2022 study has shown that, although predominately caused by E. faecalis, enterococcal bacteraemia in Australia is frequently caused by ampicillin-resistant, high-level gentamicin-resistant and vancomycin-resistant E. faecium. Furthermore, the percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia (46.9%) remains significantly higher than that seen in most European countries. In addition to being a significant cause of healthcare-associated sepsis, the emergence of multiple multi-resistant hospital-adapted E. faecium strains has become a major infection control issue in Australian hospitals.

Of particular concern, one E. faecalis with a daptomycin MIC of 8.0 mg/L harboured the F478L GdpD mutation and one E. faecium with a daptomycin MIC of 24.0 mg/L harboured the A20D Cls mutation, mutations both known to be associated with daptomycin resistance. Two E. faecium, one with a linezolid MIC ≥ 256 mg/L and the other with a linezolid MIC of 16 mg/L, harboured the 23S rRNA G2576T mutation which is associated with linezolid resistance in enterococci. Linezolid and daptomycin are considered ‘last-line’ antimicrobials used in the treatment of enterococcal bacteraemia; resistance to these drugs is a public health concern.

Ongoing studies on the enterococcal genome will contribute to our understanding of the rapid and continuing evolution of enterococci in the hospital environment and will assist in preventing their nosocomial transmission.

# Acknowledgments

This study was funded by the Australian Government Department of Health and Aged Care.

## Members of the AGAR in 2022 were:

### Australian Capital Territory

The Canberra Hospital, Peter Collignon and Susan Bradbury

### New South Wales

Children’s Hospital Westmead, Alison Kesson and Andrew Jarrett

Concord Hospital, Thomas Gottlieb and John Huynh

Gosford Hospital, Gabrielle O’Kane and Nola Hitchick

John Hunter Hospital, Hemalatha Varadhan and Bree Harris

Liverpool Hospital, Michael Maley and Helen Ziochos

Nepean Hospital, James Branley and Linda Douglass

Prince of Wales and Sydney Children’s Hospital, Monica Lahra and Peter Huntington

Royal North Shore Hospital, Angela Wong

St Vincent’s Hospital, David Lorenz

Westmead Hospital, Jon Iredell and Andrew Ginn

Wollongong Hospital, Peter Newton and Melissa Hoddle

### Northern Territory

Alice Springs Hospital, James McLeod

Royal Darwin Hospital, Rob Baird and Jann Hennessy

### Queensland

Gold Coast Hospital, Petra Derrington and Cheryl Curtis

Greenslopes Hospital and Mater Hospital Townsville, Jennifer Robson and Marianne Allen

Prince Charles Hospital, Robert Horvath

Princess Alexandra Hospital, Naomi Runnegar and Joel Douglas

Royal Brisbane and Women’s Hospital, Claire Heney and Narelle George

### South Australia

Flinders Medical Centre, Kelly Papanaoum and Xiao Ming Chen

Royal Adelaide Hospital and Women’s and Children’s Hospital, Morgyn Warner and Kija Smith

### Tasmania

Launceston General Hospital, Pankaja Kalukottege and Brooke Woolley

Royal Hobart Hospital, Louise Cooley and David Jones

### Victoria

Alfred Hospital, Adam Jenney and Jacqueline Williams

Austin Health, Marcel Leroi and Elizabeth Grabsch

Dandenong Hospital, Tony Korman and Kathryn Cisera

Monash Medical Centre and Monash Children’s Hospital, Tony Korman and Despina Kotsanas,

Royal Children’s Hospital, Andrew Daley and Gena Gonis

Royal Melbourne Hospital, Katherine Bond and Rose Cotronei

St Vincent’s Hospital, Amy Crowe and Lisa Brenton

### Western Australia

Fiona Stanley Hospital, Shakeel Mowlaboccus and Denise Daley

Joondalup Hospital, Shalinie Perera and Ian Meyer

Perth Children’s Hospital, Christopher Blyth

Regional Hospitals– Northwest WA, Michael Leung

Royal Perth Hospital, Owen Robinson and Geoffrey Coombs

Sir Charles Gairdner Hospital, Ronan Murray and Jacinta Bowman

St John Of God Hospital, Murdoch, Sudha Pottumarthy-Boddu and Jacqueline Foster

# Author details

Prof Geoffrey W Coombs,1,2,3

Ms Denise A Daley,2,3

Ms Princy Shoby,1

Dr Shakeel Mowlaboccus,1,2

on behalf of the Australian Group on Antimicrobial Resistance

1. Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia
2. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
3. Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

## Corresponding author

Prof Geoffrey Coombs

Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia

Telephone: +61 8 6152 2397

Email: g.coombs@murdoch.edu.au

# References

1. Pinholt M, Ostergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect. 2014;20(2):145–51. doi: https://doi.org/ 10.1111/1469-0691.12236.
2. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163–70. doi: https://doi.org/10.1016/j.diagmicrobio.2006.12.022.
3. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990;3(1):46–65. doi: https://doi.org/10.1128/CMR.3.1.46.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12. doi: https://doi.org/10.1086/595011.
5. Christiansen KJ, Turnidge JD, Bell JM, George NM, Pearson JC, Australian Group on Antimicrobian Resistance. Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell Q Rep. 2007;31(4):392–7.
6. Coombs GW, Daley D, Pearson JC, Ingram PR. A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia. Pathology. 2014;46(1):73–5. doi: https://doi.org/10.1097/PAT.0000000000000038.
7. Coombs GW, Pearson JC, Daley DA, Le T, Robinson OJ, Gottlieb T et al. Molecular epidemiology of enterococcal bacteremia in Australia. J Clin Microbiol. 2014;52(3):897–905. doi: https://doi.org/10.1128/JCM.03286-13.
8. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 33rd ed. CLSI supplement M100. Wayne, PA: CLSI; 3 March 2023.
9. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1. Basel: EUCAST; 29 June 2023. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\_files/Breakpoint\_tables/v\_13.1\_Breakpoint\_Tables.pdf.
10. Coombs GW, Daley DA, Lee YT, Pang S. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.42.
11. Coombs GW, Daley DA, Mowlaboccus S, Lee YT, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.19.
12. Coombs GW, Daley DA, Mowlaboccus S, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.72.
13. Coombs GW, Daley DA, Yee NWT, Shoby P, Mowlaboccus S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2020. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/cdi.2022.46.17.
14. Coombs GW, Daley DA, Yee NWT, Shoby P, Mowlaboccus S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) – Bloodstream Infection Annual Report 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/cdi.2022.46.77.
15. European Centre for Disease Prevention and Control (ECDC). European Antimicrobial Resistance Surveillance Network (EARS-Net). [Webpage.] Solna: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data.
16. ECDC. Surveillance Atlas of Infectious Diseases. [Webpage.] Solna: ECDC; 28 April 2023. Available from: https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Christina Bareja

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection, Australian Government Department of Health and Aged Care, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** cdi.editor@health.gov.au

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: cdi.editor@health.gov.au.

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2023 Commonwealth of Australia as represented by the Department of Health and Aged Care

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.
<http://www.health.gov.au/cdna>